No allergy against the stock market
Bagneux - DBV Technologies is planning an IPO on Euronext Paris. The French pharmaceutical group specialising in the treatment of allergies was founded in 2002. DBV's proprietary technology Viaskin is used to administer an allergen through the skin without the need of an injection. This epicutaneous process allows significantly to reduce the risk of an allergic reaction. DBV's most advanced product is in Phase II testing to treat peanut allergy in children and adults. The pipeline has two other entries. Milk Viaskin against cow's milk allergies for kids will probably enter a phase II study in 2013, while Viaskin for HDM allergy to dust mites for children will start a phase I study in 2013, the company says. DBV thinks that the three allergies in the pipeline represent a market potential of more than €5bn.